Woodline Partners LP Supernus Pharmaceuticals, Inc. Transaction History
Woodline Partners LP
- $13.5 Billion
- Q4 2024
A detailed history of Woodline Partners LP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 423,828 shares of SUPN stock, worth $13.6 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
423,828
Previous 188,571
124.76%
Holding current value
$13.6 Million
Previous $5.88 Million
160.67%
% of portfolio
0.11%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$333 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.3 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.3 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...